Ionis Pharmaceuticals, Inc.: all 133 studies
Page 2 of 2. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.
- A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1CompletedNCT02312011Phase 1/2
- Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 DiabetesCompletedNCT01968265Phase 2
- Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 DiabetesCompletedNCT01918865Phase 2
- Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 DiabetesCompletedNCT01885260Phase 2
- Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee ArthroplastyCompletedNCT01713361Phase 2
- Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial FibrillationCompletedNCT01710852Phase 2
- Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 DiabetesTerminatedNCT01647308Phase 2
- Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced CancersCompletedNCT01563302Phase 1/2
- Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in HypertriglyceridemiaCompletedNCT01529424Phase 2
- Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid ArthritisCompletedNCT01414101Phase 2
- Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and PaclitaxelCompletedNCT01234038Phase 1/2
- Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)CompletedNCT01234025Phase 1/2
- Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene MutationsCompletedNCT01041222Phase 1
- Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy VolunteersCompletedNCT00836225Phase 1
- Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy VolunteersCompletedNCT00734240Phase 1
- Safety Study of ISIS 325568 in Healthy VolunteersCompletedNCT00519727Phase 1
- Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With SulfonylureaCompletedNCT00455598Phase 2
- Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715CompletedNCT00365781Phase 1
- Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior TreatmentCompletedNCT00330330Phase 2
- Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 DiabeticsTerminatedNCT00330200Phase 2
- Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With SulfonylureaWithdrawnNCT00327626Phase 2
- ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.CompletedNCT00063830Phase 2
- ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative ColitisCompletedNCT00063414Phase 2
- Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two DrugsCompletedNCT00062816Phase 1/2
- ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid ArthritisCompletedNCT00048321Phase 2
- Alicaforsen (ISIS 2302) in Patients With Active Crohn's DiseaseCompletedNCT00048295Phase 3
- Alicaforsen (ISIS 2302) in Patients With Active Crohn's DiseaseCompletedNCT00048113Phase 3
- ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus InfectionsCompletedNCT00035945Phase 2
- Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung CancerCompletedNCT00017407Phase 3
- The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the EyesCompletedNCT00002356Phase 2
- A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the EyesCompletedNCT00002355Not applicable
- A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus RetinitisCompletedNCT00002187Not applicable
- A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )CompletedNCT00002156Phase 2